Sayed Hamid Musawi

Dr. Sayed Hamid Mousavi is currently employed at Kateb University as the Assistant Professor for Clinical Biochemistry Department of Medical Sciences, Kateb University since 2011. Since 2011, I have been head of health committee of the Afghanistan Hemophilia Patients Association (AHPA). From 2015 to 2017, I worked in Professor Zeinli’s genetic laboratory in Tehran, Iran, and I was trained in all the necessary courses for the diagnosis of genetic diseases, and more than 200 types of genetic diseases were diagnosed with all molecular devices such as I learned PCR, sequences, etc. Since 2017, as the director of the Afghanistan National Charity Organization for Specific Diseases (ANCOSD), I have conducted many scientific projects, research on specific diseases such as hemophilia, thalassemia, hepatitis, etc.Since 2017, I have been the managing director of the first health weekly called LABKHAND, which focused on specific diseases.And since 2020, I have been working as the director of research at Kateb University. Dr. Mousavi has a PhD in field of Clinical Biochemistry specialized from Tarbiat Modares University in Tehran (2018). He has a master’s degree in Clinical Biochemistry (2011). He got his bachelor’s degree in Laboratory sciences from Zabol University in (2007). Dr. Mousavi has published books name “Biochemistry 1, Biochemistry 2, Molecular Biology, Practical Biochemistry and Nutrition” in Kabul, Afghanistan, , And he has several other articles and research work experience such as follows:

Published Articles:

  1. Mapping the changes on incidence, case fatality rates and recovery proportion of COVID-19 in Afghanistan using geographical information systems. SH Mousavi, SU Zahid, K Wardak, KA Azimi, SMR Hosseini, M Wafaee and et al. Archives of Medical Research. 2020 Jun 18.DOI:10.1016/j.arcmed.2020.06.010.
  2. Coronavirus disease 2019 (COVID-19) outbreak in Afghanistan; measures and challenges: SH Mousavi, M Abdi, SU Zahid, K Wardak. Infection Control & Hospital Epidemiology, 1-4, 2020/5/15.DOI:  https://doi.org/10.1017/ice.2020.240.
  3. COVID-19 the current situation in Afghanistan: Jaffer Shah, Sedighe Karimzadeh,Tareq Mohammed Ali Al-Ahdal, Sayed Hamid Mousavi, Shafi Ullah Zahid, Nguyen Tien Huy. Lancet Glob Health. 2020.Published Online ,April 2, 2020, https://doi.org/10.1016/S2214-109X(20)30124-8.
  4. The first COVID-19 casein Afghanistan acquired from Iran. Sayed H Mousavi, Jaffer Shah, Hoang T N Giang, Tareq M A Al-Ahdal, Shafi U Zahid, Fardina Temory, Feda M Paikan, Sedighe Karimzadeh, Nguyen T Huy. Lancet Infect Dis 2020. Published Online March 23, 2020.https://doi.org/10.1016/S1473-3099(20)30231-0.
  5. A large deletion, spanning exons 1 to 25 of F8 gene, and a high titer factor VIII inhibitor, in severe hemophilia A. Sayed Hamid Mousavi, Seyed Alireza Mesbah-Namin, Sirous Zeinali, Mohammad Jazebi, Ali Dabbagh, Sayed Mohammad Reza Hosseini, Fatemeh Zafarghandi Motlagh, Yavar Shiravand, Akbar Dorgalaleh.International journal of laboratory hematology,2020,;00:1–3. DOI: 10.1111/ijlh.13174

6.Investigating the influence of LCT rs3754689 polymorphism on inhibitor development in Iranian and Afghan patients with severe hemophilia A. Sobhan Bahrami Zadegan, Sayed H. Mousavi, Narges Damavandi, Mohammad H. Samiee Aref and Sirous Zeinali. Blood Coagulation and Fibrinolysis 2019, 30:00–00.

  1. Hemophilia A in Afghanistan, the first report. SH Mousavi, S Tabibian, H Motlagh, A Dorgalaleh. Blood Coagulation & Fibrinolysis.2019; 30 (7), 357-360. doi: 10.1097/MBC.0000000000000853
  2. Prevalence and Risk Factors of Hepatitis B, Hepatitis C and HIV Viruses Among People Who Use Drugs (PWUD) in Kabul, Health Care Facilities. H Rasekh, HM Naimi, SH Mousavi. 2019;Hepatitis Monthly 19 (7).
  3. Determinants of Quality of Life in Children and Adolescents with Hemophilia in Kabul, Afghanistan Sayed Hamid Mousavi,Mohammad Saaid Dayer, Fatemeh Pourhaji,Mohammad-Hossein Delshad. Arch Iran Med. July 2019;22(7):384-389.
  4. First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan. Mousavi SH, Khairkhah N, Bahri TD, Anvar A, Saraji AA, Behnava B, et al. Scientific reports. 2019;9(1):7259.

11.Factor XIII Deficiency in Western Afghanistan due to a Novel F13A Gene Mutation.SH Mousavi, S Zeinali, SA Mesbah‐Namin,M Shams,A Dorgalaleh. International journal of laboratory hematology, 28 May 2019. https://doi.org/10.1111/ijlh.13050.

  1. Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A: a first report. Mousavi SH, Mesbah-Namin SA, Rezaie N, Jazebi M, Zeinali S.Blood Coagulation & Fibrinolysis. 2018;29(8):697-700.
  2. Evaluation of antibiotic prescribing in Kabul, Afghanistan. Mousavi SH, Roien R, Ramozi A European Journal of Internal Medicine. 2018;55:e13-e5.

14.Frequencies of intron 1 and 22 inversions of factor VIII gene: A first report in Afghan patients with severe haemophilia A. SH Mousavi, SA Mesbah‐Namin, N Rezaie, S Zeinali. Haemophilia .2018;24 (3), e157-e160.

  1. Hemophilia A. Congenital Bleeding Disorders:Gholami MS, Valikhani M, Dorgalaleh A, Mousavi SH, Pezeshkpoor B. Springer; 2018. p. 103-37.

Sharing is caring!



Print

Leave a Reply

Be the First to Comment!

avatar
  Subscribe  
Notify of

2020-12-01